Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][8]. Core Insights - The company is a leading player in the domestic wearable SoC market, focusing on ultra-low power technology and wireless communication solutions for smart wearable and smart home devices [4]. - The revenue from smartwatch chips is continuously increasing, significantly contributing to the company's high growth [5]. - The AI glasses market presents a vast opportunity, potentially becoming the company's third growth curve [6]. Financial Performance - In 2024, the company reported a revenue of 3.263 billion yuan, a year-on-year increase of 49.94%, and a net profit of 460 million yuan, up 272.47% [5]. - For Q1 2025, the company achieved a revenue of 999.5 million yuan, reflecting a 52.25% year-on-year growth, with a net profit of 191 million yuan, a staggering increase of 590.22% [5]. - The gross margin improved from 32.93% in Q1 2024 to 38.47% in Q1 2025, primarily due to the rising revenue share from smartwatch chips [5]. Growth Projections - The company is expected to achieve net profits of 815 million yuan, 1.257 billion yuan, and 1.725 billion yuan for the years 2025, 2026, and 2027, respectively, with growth rates of 77.0%, 54.2%, and 37.2% [8][24]. - The projected revenue for 2025 is 4.793 billion yuan, with a year-on-year growth of 46.9% [10]. Market Position - The company has established itself in the supply chains of major global Android smartphone brands and leading audio manufacturers, enhancing its market presence [7][24]. - The company is currently providing MCU-level SoC solutions for AI glasses and is developing SoC-level solutions, indicating a strategic move into a new product line [6][24].

Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board Artificial Intelligence Index (950180) has shown a strong increase of 1.23% as of June 3, 2025, with notable gains in constituent stocks such as Lanke Technology (688008) up by 5.57% and Fudan Microelectronics (688385) up by 3.75% [2] - The upcoming Global Artificial Intelligence Technology Conference (GAITC 2025) will be held in Hangzhou from June 7 to 8, focusing on themes of "crossing, integration, mutual growth, and win-win" [2] - CITIC Securities reports that the process of re-evaluating the value of China's technology industry is ongoing, recommending investors to focus on the expansion of the AI ecosystem and the investment opportunities arising from application implementation [2] ETF Performance - The Sci-Tech AI ETF (588790) closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Artificial Intelligence Index, which includes 30 large-cap companies providing resources, technology, and application support for AI [3] - The ETF has seen a significant growth in scale, increasing by 82.29 million yuan in the past week, ranking it in the top one-sixth among comparable funds [3] - As of the latest data, the ETF's shares reached a new high of 5.578 billion shares, also placing it in the top one-sixth among comparable funds [3] Fund Flows - The Sci-Tech AI ETF has experienced continuous net inflows over the past five days, with a peak single-day net inflow of 42.23 million yuan, totaling 115 million yuan in net inflows [3] - The latest margin buying amount for the ETF reached 11.92 million yuan, with a margin balance of 72.73 million yuan [3] Return Metrics - As of May 30, 2025, the Sci-Tech AI ETF has achieved a maximum monthly return of 15.59% since its inception, with the longest consecutive monthly gain being two months and a total increase of 26.17% [4] - The ETF has a relative drawdown of 0.40% compared to its benchmark since inception [4] Fee Structure and Tracking Accuracy - The management fee for the Sci-Tech AI ETF is 0.50%, and the custody fee is 0.10%, making it the lowest among comparable funds [5] - The ETF has a tracking error of 0.016% over the past three months, indicating high tracking accuracy compared to similar funds [5] Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the ETF is 116.45, which is in the 16.67th percentile over the past year, indicating a valuation lower than 83.33% of the time in the past year [5] - The top ten weighted stocks in the index account for 70.6% of the total, with Lanke Technology (688008) holding the highest weight at 10.47% [5][7]

A股重磅。 5月30日，中证指数公司发布公告称，将调整沪深300、中证500、中证1000、中证A50、中证A100、中证A500等指数样本，6月13日收市后也即6月16日起正式生 效。同时，上海证券交易所与中证指数有限公司也联合发布公告称，将调整上证50、上证180、上证380、科创50等指数样本，也是6月13日收市后也即6月16日起 生效。 沪深300等6大指数合计更换187只样本 5月30日，中证指数有限公司还宣布将调整沪深300、中证500、中证1000、中证A50、中证A100、中证A500等指数样本，此次调整为指数样本的定期例行调整， 定期调整方案将于6月13日收市后也即6月16日起正式生效。 | | | | | | | 调出名单 | | | 调入名单 | | --- | --- | --- | --- | | 证券代码 | 证券名称 | 证券代码 | 证券名称 | | 000401 | 童东水泥 | 000062 | 深圳华强 | | 000778 | 新兴铸管 | 000415 | 渤海租赁 | | 000818 | 航锦科技 | 000429 | 粤高速 A | | 000998 | 隆平高 ...

Core Points - The company has adjusted its profit distribution plan for 2024, maintaining a cash dividend of 1.20 CNY per share while increasing the total cash dividend amount from 143,596,018.80 CNY to 143,675,436.00 CNY [2][7] - The company plans to increase its capital reserve by issuing 4 new shares for every 10 shares held, with the total number of shares to be issued adjusted from 47,865,340 to 47,891,812 [2][7] - The adjustments were made due to the completion of the first phase of the 2023 restricted stock incentive plan, which resulted in a decrease in the number of shares in the company's repurchase account [2][6][7] Profit Distribution and Capital Increase Plan - Prior to the adjustment, the company planned to distribute a cash dividend of 12 CNY per 10 shares, totaling 143,596,018.80 CNY, which accounted for 31.18% of the net profit attributable to shareholders for 2024 [3][7] - After the adjustment, the cash dividend remains at 12 CNY per 10 shares, with the total cash dividend now amounting to 143,675,436.00 CNY, representing 31.27% of the net profit for 2024 [7] - The total number of shares after the capital increase will rise to 167,937,371 shares [7] Shareholder Meeting - The annual shareholder meeting was held on May 29, 2025, where all proposed resolutions were approved, including the profit distribution and capital increase plan [10][12] - The meeting was conducted in compliance with legal and regulatory requirements, with all board members present [12][13] Stock Incentive Plan - The company completed the first phase of the 2023 restricted stock incentive plan, with a total of 66,181 shares being vested [17][26] - The shares for this incentive plan were sourced from shares repurchased from the secondary market, ensuring that the total share capital remains unchanged [25][26]

Core Points - The company announced the results of the first vesting period for its 2023 restricted stock incentive plan, with a total of 66,181 shares vested [1][7] - The vested shares were sourced from the company's repurchase of its A-share common stock from the secondary market [1][7] - A total of 33 individuals are included as incentive recipients, with specific allocations for technical and business backbone personnel [6][7] Group 1: Incentive Plan Overview - The decision-making process for the incentive plan involved multiple board and supervisory meetings, with independent directors providing opinions [2][4] - The plan was publicly disclosed on the Shanghai Stock Exchange, and no objections were raised during the internal announcement period [3][4] - The plan includes a mechanism for adjusting the grant price and has undergone several reviews and approvals throughout its implementation [5][6] Group 2: Share Allocation Details - The total number of shares granted to the incentive recipients is 222,136, with 66,181 shares now vested [6][7] - The allocation includes 200,598 shares for technical backbone personnel and 21,538 shares for business backbone personnel, representing 29.77% and 30% of their respective total allocations [6][7] - The shares vested do not include any for the company's directors and senior management [6][7] Group 3: Financial and Regulatory Compliance - The company received a total of RMB 4,240,943.24 from the incentive recipients as subscription payments, which were deposited in a designated bank account [7] - The total number of shares remains unchanged at 120,045,559, as the shares were sourced from repurchased stock [7] - The company has completed the necessary registration procedures for the vested shares, confirmed by the China Securities Depository and Clearing Corporation [7]

证券代码：688608 证券简称：恒玄科技 公告编号：2025-028 恒玄科技（上海）股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 29 日 （二） 股东大会召开的地点：上海市浦东新区金科路 2889 弄长泰广场 B 座公 司会议室 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 3、 董事会秘书李广平女士出席了本次会议。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 227 | | --- | --- | | 普通股股东人数 | 227 | | 2、出席会议的股东所持有的表决权数量 | 49,313,579 | | 普通股股东所持有表决权数量 | 49,313,579 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41 ...

重要内容提示： 恒玄科技（上海）股份有限公司（以下简称"公司"）调整 2024 利润分配 拟每股派发现金红利 1.20 元（含税）不变，现金分红总额由人民币 143,596,018.80 元（含税）调整为 143,675,436.00 元（含税）。 公司 2024 年度拟向全体股东每 10 股以公积金转增 4 股不变，转增股本 的数量由 47,865,340 股调整为 47,891,812 股（最终以中国证券登记结算有限责任 公司上海分公司登记结果为准）。 本次调整原因：自公司 2024 年度利润分配及资本公积转增股本方案披露 之日起至本公告披露日，完成 2023 年限制性股票激励计划预留授予部分第一期 归属共计 6.6181 万股，股票来源于公司回购专用证券账户回购的股票。上述事 项导致公司回购专用证券账户中股份数由 382,210 股减少至 316,029 股，公司总 股 本扣 除公 司回 购 专用 证券 账 户中 股份 的基 数 由 119,663,349 股 调整 为 119,729,530 股。公司拟维持每股分配比例及每股转增比例不变，相应调整分配 及转增总额。 一、调整前利润分配及资本公积转增股本 ...

关于公司 2023 年限制性股票激励计划预留授予部分 第一个归属期归属结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司相关业务规定，恒玄科技（上海）股份有限公司（以下简称"公 司"）于 2025 年 5 月 29 日收到中国证券登记结算有限责任公司上海分公司出具 的《过户登记确认书》，公司完成了 2023 年限制性股票激励计划（以下简称"本 次激励计划"）预留授予部分第一个归属期的股份登记工作。现将有关情况公告 如下： 一、本次限制性股票激励计划的决策程序和信息披露情况 证券代码：688608 证券简称：恒玄科技 公告编号：2025-027 恒玄科技（上海）股份有限公司 （一）2023 年 8 月 1 日，公司召开第二届董事会第六次会议，审议通过了 《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司 <2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授 权董事 ...

上海市锦天城律师事务所关于 恒玄科技（上海）股份有限公司 2024 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于恒玄科技（上海）股份有限公司 2024 年年度股东大会的法律意见书 致：恒玄科技（上海）股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共和国 公司法》（以下简称"《公司法》"）和中国证券监督管理委员会（以下简称"中国 证监会"）《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和 有关规范性文件的要求，上海市锦天城律师事务所（以下简称"本所"）接受恒 玄科技（上海）股份有限公司（以下简称"恒玄科技"或"公司"）的委托，指 派本所律师参加恒玄科技 2024 年年度股东大会（以下简称"本次股东大会"）， 并出具本法律意见书。 本法律意见书仅供本次股东大会之目的使用。本所律师同意将本法律意见书 随恒玄科技本次股东大会其他信息披露资料一并公告。 本所律师根据《证 ...

Core Viewpoint - The Chinese innovative pharmaceutical industry is transitioning from imitation to original innovation, with significant growth in outbound transactions and a promising future for internationalization [4] Group 1: Market Performance - As of May 29, 2025, the Sci-Tech Innovation Board 100 Index (000698) rose by 1.63%, with notable increases in constituent stocks such as Borui Pharmaceutical (688166) up 9.66% and Zhixiang Jintai (688443) up 6.57% [3] - The Sci-Tech 100 Index ETF (588030) increased by 1.60%, with a latest price of 0.95 yuan and a turnover rate of 1.16%, totaling 71.56 million yuan in transactions [3] - Over the past year, the average daily transaction volume of the Sci-Tech 100 Index ETF reached 424 million yuan, ranking first among comparable funds [3] Group 2: Fund Growth and Performance - The Sci-Tech 100 Index ETF saw a significant increase in scale, growing by 94.45 million yuan over the past two weeks, ranking second among comparable funds [4] - In the past week, the ETF's shares increased by 99 million, also ranking first among comparable funds [5] - The ETF has experienced a net inflow of 71.08 million yuan over the last five trading days, indicating strong investor interest [5] Group 3: Financial Metrics - As of May 28, 2025, the Sci-Tech 100 Index ETF's net value increased by 19.94% over the past year, with a maximum monthly return of 27.67% since inception [5] - The ETF's management fee is 0.15% and the custody fee is 0.05%, making it the lowest among comparable funds [5] - The tracking error for the ETF over the past six months is 0.016%, indicating high tracking precision compared to similar funds [5] Group 4: Industry Insights - From the beginning of 2025 to the present, the total outbound transaction amount for innovative drugs has reached 45.5 billion USD, with upfront payments totaling 2.2 billion USD, suggesting a record year ahead [4] - Most domestic innovative drugs currently in the U.S. are in clinical stages, with significant potential for future growth as they progress towards commercialization [4]